Mifobate

Overview

Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity ( IC 50 =140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα , PPARβ, or the farnesoid X receptor ( FXR ). Mifobate (SR-202) shows antiobesity and antidiabetic effects.

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Obesity | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-100277
• CAS No.: 76541-72-5
• Molecular Formula: C11H17ClO7P2
• Molecular Weight: 358.65
• Purity: 99.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.97 mM); Clear solution
• Availability: In-stock

Source

Original product source